左氧氟沙星联合舒利迭对慢性阻塞性肺疾病急性加重期患者血清SAA、TGF-β1、copeptin、sICAM-1水平的影响  

Effects of Levofloxacin combined with Seretide on the Serum SAA,TGF-β1, Copeptin, and sICAM-1 Levels of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：蔡丹磊[1] 黄中伟[1] 蔡琦[1] 王霆[1] 姜岱山 CAI Dan-lei,HUANG Zhong-wei,CAI Qi,WANG Ting,JIANG Dai-shan(Hospital Affiliated to Nantong University, Nantong, Jiangsu, 226001, Chin)

机构地区：[1]南通大学附属医院,江苏南通226001

出　　处：《现代生物医学进展》2018年第4期709-712,717,共5页Progress in Modern Biomedicine

基　　金：江苏省自然科学基金项目(BS2010019)

摘　　要：目的:探讨左氧氟沙星联合舒利迭吸入对慢性阻塞性肺疾病急性加重期(AECOPD)患者血清淀粉样蛋白A(SAA)、转化生长因子-β1(TGF-β1)、羟基端糖肽(copeptin)、可溶性细胞黏附因子-1(sICAM-1)水平的影响。方法:选择我院2014年12月~2016年12月收治的92例AECOPD患者并按抽签法分为对照组和实验组,每组46例。对照组接受常规治疗,实验组基于对照组加以左氧氟沙星联合舒利迭吸入治疗。比较两组临床疗效,致力前后血清SAA、TGF-β1、copeptin、sICAM-1、二氧化碳分压(PaCO_2)、氧分压(PaO_2)、第1秒用力呼气容积(FEV1)、肺活量(FVC)、临床症状积分的变化及不良反应的发生情况。结果:治疗后,实验组临床总有效率选择高于对照组(P<0.05)。两组治疗后血清SAA、TGF-β1、copeptin、sICAM-1、PaCO_2、临床症状积分均较治疗前显著下降,且实验组以上指标均明显低于对照组(P<0.05);两组治疗后PaO_2、FEV1、FVC均叫治疗前明显上升,且实验组以上指标均显著高于对照组(P<0.05)。两组不良反应的发生率比较差异无统计学意义(P>0.05)。结论:左氧氟沙星联合舒利迭吸入对AECOPD患者的临床效果明显优于常规治疗,能够降低患者血清SAA、TGF-β1、copeptin、sICAM-1水平,改善肺功能。Objective： To investigate the effects of levofloxacin and seretide on the serum levels of amyloid A（SAA）,transforming growth factor-β1（TGF-β1）, hydroxyl glycopeptide（copeptin） and soluble cell adhesion factor-1（sICAM 1） in patients with the acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods： 92 cases of AECOPD who were treated in our hospital from December 2014 to December 2016 were selected and randomly divided into the control group and the experimental group.The control group was treated with routine method, while the experimental group was treated with levofloxacin and seretide based on control group. Then the clinical curative effect, the serum levels of SAA, TGF-β1, copeptin and sICAM-1, the partial pressure of carbon dioxide（PaCO2）, oxygen partial pressure（PaO2）, forced expiratory volume at the first second（FEV1） and forced vital capacity（FVC）,clinical symptoms integral and incidence of adverse reactions were observed and compared between two groups. Results： After treatment,the total effective rate of experimental group was more effective than that of the control group（P〈0.05）. The serum levels of SAA,TGF-β1, copeptin, sICAM 1 and PaCO2, the clinical symptom score of two group significantly decreased than those before treatment,which were significantly lower in the experimental group than those of the control group（P〈0.05）. The PaO2, FEV1 and FVC of two group increased than those before treatment, which were higher in the experimental group than those of the control group（P〈0.05）. The incidence of adverse reactions showed no difference between the two groups（P〈0.05）. Conclusion： Levofloxacin and seretide was effective in the treatment of AECOPD, which can reduce the serum SAA, TGF-β1, copeptin and sICAM 1 levels and improve the lung function.

关 键 词：慢性阻塞性肺疾病急性加重期 左氧氟沙星 舒利迭吸入 淀粉样蛋白A 转化生长因子-β1 羟基端糖肽 可溶性细胞黏附因子-1 

分 类 号：R563[医药卫生—呼吸系统]